Oxymorphone (likely what you meant by “Oxymorphon”) is a potent semi-synthetic opioid analgesic derived from thebaine, used primarily for severe pain management when other treatments fail. Here’s a concise breakdown:

Key Facts

• Chemical Structure: C₁₇H₁₉NO₄; it’s a metabolite of oxycodone and about 10x more potent than morphine on a mg-for-mg basis due to higher affinity for μ-opioid receptors.
• Brand Names: Opana (extended-release), Opana ER (discontinued in the US due to abuse risks via injection after crushing).
• Medical Uses:
  • Moderate-to-severe acute pain (e.g., post-surgery).
  • Chronic pain in opioid-tolerant patients.
  • Available as oral tablets, extended-release formulations, or injectable.

Mechanism of Action

Binds to opioid receptors in the brain and spinal cord, inhibiting pain signals, altering pain perception, and producing euphoria. Half-life: ~9-11 hours (oral).

Dosage (Adults, Approximate Guidelines)

Always follow prescribing info; requires opioid tolerance for ER forms.

Side Effects & Risks

• Common: Nausea, constipation, drowsiness, itching.
• Serious: Respiratory depression, addiction, overdose (pinpoint pupils, coma). High abuse potential—Schedule II controlled substance.
• Overdose Antidote: Naloxone (Narcan).

Evidence & Studies

• Efficacy confirmed in RCTs (e.g., JAMA 2005 study showed superior pain relief vs. oxycodone in post-op settings).
• CDC data: Contributed to opioid crisis; FDA halted ER form in 2017 due to IV abuse spikes (90% bioavailability when crushed/injected vs. 10% oral).

Warning: High risk of dependence/tolerance. Not for mild pain or non-tolerant patients. Consult a doctor—misuse can be fatal. If this is for personal use, seek professional medical advice.